|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.670 USD | +2.30% |
|
+12.18% | -35.82% |
| Market Cap | 172M 149M 137M 128M 240M 16.35B 244M 1.62B 630M 7.95B 645M 631M 27.53B | P/E Ratio 2026 * |
-7.05x | P/E Ratio 2027 * | -7.91x |
|---|---|---|---|---|---|
| Enterprise Value | 172M 149M 137M 128M 240M 16.35B 244M 1.62B 630M 7.95B 645M 631M 27.53B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
69.66% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Galectin Therapeutics Inc.
| 1 day | +2.30% | ||
| 1 week | +12.18% | ||
| Current month | +5.95% | ||
| 1 month | +20.81% | ||
| 3 months | -11.30% | ||
| 6 months | -53.24% | ||
| Current year | -35.82% |
| 1 week | 2.32 | 2.76 | |
| 1 month | 2.07 | 3.11 | |
| Current year | 2.02 | 4.35 | |
| 1 year | 1.33 | 7.13 | |
| 3 years | 0.73 | 7.13 | |
| 5 years | 0.73 | 7.13 | |
| 10 years | 0.49 | 9.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Joel Lewis
CEO | Chief Executive Officer | 56 | 2020-09-01 |
Jack Callicutt
DFI | Director of Finance/CFO | 58 | 2013-06-30 |
| Chief Tech/Sci/R&D Officer | - | 2023-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilbert Amelio
BRD | Director/Board Member | 83 | 2009-02-11 |
Kevin Freeman
BRD | Director/Board Member | 65 | 2011-04-30 |
Harold Shlevin
BRD | Director/Board Member | 77 | 2019-11-30 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 05-25 | Fiscal year | Chief Technology Officer | 1,704 | 0.0026% | ||
| 03-11 | Free | Director | 60,000 | 0.0931% | ||
| 03-11 | Other | Director | 0 | 0% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.30% | +12.18% | +102.27% | +75.66% | 172M | ||
| -0.35% | -0.22% | -15.03% | -12.88% | 42.96B | ||
| +3.11% | -1.17% | +277.22% | +502.47% | 31.73B | ||
| +0.22% | -2.90% | +14.25% | -12.16% | 30.22B | ||
| +1.62% | -5.52% | +0.79% | +22.42% | 28.94B | ||
| +4.09% | -1.98% | +11.99% | +17.37% | 23.87B | ||
| -1.63% | +1.89% | +54.59% | +124.83% | 13.57B | ||
| -0.40% | -1.48% | +7.48% | +7.12% | 12.96B | ||
| +1.14% | -0.36% | - | - | 13.39B | ||
| -0.74% | -2.47% | +102.47% | +80.26% | 12.2B | ||
| Average | +0.94% | -0.51% | +61.78% | +89.45% | 21B | |
| Weighted average by Cap. | +1.02% | -1.08% | +55.92% | +95.94% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -24.6M -21.27M -19.59M -18.35M -34.41M -2.34B -34.93M -232M -90.19M -1.14B -92.32M -90.35M -3.94B | -22.9M -19.8M -18.24M -17.08M -32.03M -2.18B -32.51M -216M -83.96M -1.06B -85.94M -84.11M -3.67B |
| Net Debt | - | - |
Employees
9
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-12 | 2.670 $ | +2.30% | 282,113 |
| 26-06-11 | 2.610 $ | +9.66% | 304,645 |
| 26-06-10 | 2.380 $ | -1.24% | 263,365 |
| 26-06-09 | 2.410 $ | +0.42% | 294,959 |
| 26-06-08 | 2.400 $ | +3.00% | 193,300 |
Sell
Buy

Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.670USD
Average target price
11.00USD
Spread / Average Target
+311.99%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GALT Stock
Select your edition
All financial news and data tailored to specific country editions

















